Driving Biopharmaceutical Advancement of Evidence-Based, Cannabinoid Products
Who We Are
Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments
We are an international biopharmaceutical company focused on the research, development, and commercialization of cannabis-derived products, particularly in the field of medical cannabis. Founded in Canada, we emphasize the development of advanced formulations and delivery systems for cannabinoids, aiming to meet various therapeutic needs. We work on developing products for different health conditions, and our work includes a focus on science, innovation, and clinical development.
Corporate Overview
Corporate Highlights
4 commercial stage business pillars
30+ Commercialized Proprietary products
Addressing a global market opportunity
Scientific Platform
Established industry leading scientific infrastructure
JLABS @Johnson and Johnson incubated – at MaRS
Indication specific pharmaceutical pipeline
Partnerships with leading academic and clinical institutions
Intellectual Property and Brands Owned by Avicanna
Medical Cannabis Products and RHO Phyto – Commercial
Medical Cannabis Pharmacy Platform – Launched August
Pharmaceutical Products – In development and registration stages
Active Pharmaceutical Ingredients – Aureus Santa Marta
Four Commercial Stage Business Pillars
Avicanna’s scientific platform has resulted in 30+ proprietary formulations and commercial products
Including medical cannabis, medical cannabis care, Pharmaceutical products and active pharmaceutical ingredients
Medical Cannabis Care Platform
Medical Cannabis Products
Pharmaceutical Products
Active Pharmaceutical Ingredients
Industry Leading Scientific Platform
Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products
Scientific Platform
R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products
R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano-particle formulations.
30+
Proprietary Commercial Products
10+
Scientists
11
Canadian Government Research Grants Awarded Since 2020
4
Health Canada Cannabis Research Licenses to Avicanna or Institutional Collaborators
Several issued and pending patents
World-class Institutional Collaborations
20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions Since 2017
World-Class Institutional Collaborations
20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017
Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.
Clinical Development
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
08.08.2021
Products & Pipeline
Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products